Site Editor

Gregory J. Riely, MD, PhD

Advertisement

Advertisement

News

FDA Approval: ALK Inhibitor Ensartinib for ALK-Positive Locally Advanced or Metastatic NSCLC

News

Adding Radiotherapy to TKIs in Metastatic EGFR-Mutated NSCLC Population

Medical Literature

Unresectable, Primary NSCLC: Is SBRT of Benefit in Combination With Conventional Therapy?

News

Combination of Sintilimab and Nab-Paclitaxel in Advanced Squamous NSCLC

News

SBRT vs Minimally Invasive Surgery in NSCLC: Clinical Model May Help in Selection Process

Medical Literature

The Impact of Family Cancer History on Prognosis in Patients With NSCLC

News

Relapse Patterns From Long-Term Subgroup Analysis of IMpower010

Priti Bandi, PhD: Are U.S. States Keeping Up-to-Date With Lung Cancer Screening?

Greg Durm, MD on the Current Role of Immunotherapy for NSCLC

View More

Advertisement

JNCCN Spotlights

Repotrectinib for ROS1-Positive NSCLC

(NEW Update) Nivolumab in NSCLC

(NEW Update) Pembrolizumab in NSCLC

Dabrafenib + Trametinib (Tafinlar + Mekinist)

(UPDATE) Nivolumab (Opdivo) in NSCLC

Sotorasib

View More

More

News

Osimertinib Approved for Treatment of Stage III NSCLC After Chemoradiotherapy

Creating Better Utility of Test Results in EGFR-Mutated Metastatic NSCLC

ESMO 2024: Can Adding Corticosteroid to Radiotherapy for NSCLC Reduce Pneumonitis?

SITC 2024: Novel Method to Predict, Assess Immunotherapy Efficacy in NSCLC

WCLC 2024: Novel Tyrosine Kinase Inhibitor vs Gefitinib in EGFR-Mutated NSCLC

ESMO 2024: Update on Encorafenib Plus Binimetinib in BRAF V600E–Mutated NSCLC

WCLC 2024: Adding JAK1 Inhibitor to Pembrolizumab in Metastatic PD-L1–Positive NSCLC

Lung Cancer Screening in Low-Risk Individuals: More Harm Than Good?

View More

Advertisement

Published

Medical Literature

Selpercatinib vs Chemotherapy for RET Fusion–Positive NSCLC: Phase III Findings

CANOPY-1: Adding Monoclonal Antibody to Immunotherapy Regimen in NSCLC

Is There a Link Between Regional Influenza Activity and Mortality Among Patients With NSCLC?

CNS Activity in NSCLC: Osimertinib Plus Chemotherapy vs Osimertinib Monotherapy

View More

Ongoing

CE Activities

Improving Lung Cancer Care Through Understanding the Patient Experience

Striving for Consensus: Current and Future Management of Metastatic Non-Small Cell Lung Cancer in Patients Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy

Implications of Recent Data Sets for the Current and Future Management of Lung Cancer

Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Lung Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

View More

Available

Clinical Trials

LATIFY: Ceralasertib Plus Durvalumab vs Docetaxel in NSCLC Whose Disease Progressed on or After Prior Anti–PD(L)1 Therapy and Platinum-Based Chemotherapy

An Open-Label, Randomized, Multicenter, Phase III Study of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations

Study of Avutometinib (VS-6766) Plus Adagrasib in KRAS G12C NSCLC Patients

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in NSCLC

View More

Resources

For Your Patients

The American Lung Association

Bonnie J. Addario Lung Cancer Foundation

Caring Ambassadors Program

Dusty Joy Foundation

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2024 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.